J. Schlessinger, Cell Signaling by Receptor Tyrosine Kinases, Cell, vol.103, issue.2, pp.211-236, 2000.
DOI : 10.1016/S0092-8674(00)00114-8

A. Ullrich and J. Schlessinger, Signal transduction by receptors with tyrosine kinase activity, Cell, vol.61, issue.2, pp.203-215, 1990.
DOI : 10.1016/0092-8674(90)90801-K

D. Slamon, W. Godolphin, L. Jones, J. Holt, S. Wong et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, vol.244, issue.4905, pp.707-719, 1989.
DOI : 10.1126/science.2470152

C. Foster and C. Gosden, Her2/neu expression in cancer: the pathologist as diagnostician or prophet?, Human Pathology, vol.34, issue.7, pp.635-643, 2003.
DOI : 10.1016/S0046-8177(03)00357-5

Y. Yarden and M. Sliwkowski, Untangling the ErbB signalling network, Nature Reviews Molecular Cell Biology, vol.2, issue.2, pp.127-164, 2001.
DOI : 10.1038/35052073

L. Pusztai and F. Esteva, Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer, Cancer Investigation, vol.9, issue.5, pp.187-91, 2006.
DOI : 10.1007/s00280-003-0728-3

R. Nahta, D. Yu, M. Hung, and G. Hortobagyi, Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer, Nature Clinical Practice Oncology, vol.59, issue.5, pp.269-80, 2006.
DOI : 10.1038/ncponc0509

E. Lowenstein, R. Daly, A. Batzer, W. Li, B. Margolis et al., The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling, Cell, vol.70, issue.3, pp.431-473, 1992.
DOI : 10.1016/0092-8674(92)90167-B

P. Chardin, D. Cussac, and S. Maignan, The Grb2 adaptor, FEBS Letters, vol.50, issue.1, pp.47-51, 1995.
DOI : 10.1016/0014-5793(95)00578-W

L. Buday and J. Downward, Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor, Cell, vol.73, issue.3, pp.611-631, 1993.
DOI : 10.1016/0092-8674(93)90146-H

M. Rozakis-adcock, R. Fernley, J. Wade, and T. Pawson, The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1, Nature, vol.363, issue.6424, pp.83-88, 1993.
DOI : 10.1038/363083a0

R. Daly and M. Binder, Sutherland RL Overexpression of the Grb2 gene in human breast cancer cell lines, Oncogene, vol.9, pp.2723-2730, 1994.

B. Verbeek, S. Adriaansen-slot, and G. Rijksen, Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens, The Journal of Pathology, vol.19, issue.2, pp.195-203, 1997.
DOI : 10.1002/(SICI)1096-9896(199710)183:2<195::AID-PATH901>3.0.CO;2-Y

A. Cheng, T. Saxton, R. Sakai, S. Kulkarni, G. Mbamalu et al., Mammalian Grb2 Regulates Multiple Steps in Embryonic Development and Malignant Transformation, Cell, vol.95, issue.6, pp.793-803, 1998.
DOI : 10.1016/S0092-8674(00)81702-X

Y. Xie and A. Pendergast, Dominant-negative Mutants of Grb2 Induced Reversal of the Transformed Phenotypes Caused by the Point Mutation-activated Rat HER-2/Neu, Journal of Biological Chemistry, vol.270, issue.51, pp.30717-30741, 1995.
DOI : 10.1074/jbc.270.51.30717

C. Garbay, W. Liu, and M. Vidal, Inhibitors of RAS signal transduction as antitumor agents, Biochemical Pharmacology, vol.60, issue.8, pp.1165-1174, 2000.
DOI : 10.1016/S0006-2952(00)00428-7

D. Cussac, M. Vidal, C. Leprince, W. Liu, F. Cornille et al., Garbay C A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity, Faseb J, vol.13, pp.31-39, 1999.

G. De-pinieux, M. Legrier, F. Poirson-bichat, Y. Courty, R. Bras-goncalves et al., Clinical and Experimental Progression of a New Model of Human Prostate Cancer and Therapeutic Approach, The American Journal of Pathology, vol.159, issue.2, pp.753-64, 2001.
DOI : 10.1016/S0002-9440(10)61746-4

M. Lewitzky, M. Harkiolaki, M. Domart, E. Jones, S. Feller et al., Mona/Gads SH3C Binding to Hematopoietic Progenitor Kinase 1 (HPK1) Combines an Atypical SH3 Binding Motif, R/KXXK, with a Classical PXXP Motif Embedded in a Polyproline Type II (PPII) Helix, Journal of Biological Chemistry, vol.279, issue.27, pp.28724-28756, 2004.
DOI : 10.1074/jbc.M402745200

B. Guyot and G. Mouchiroud, Characterization of promoter elements directing Mona/Gads molecular adapter expression in T and myelomonocytic cells: involvement of the AML-1 transcription factor, Journal of Leukocyte Biology, vol.73, issue.2, pp.263-72, 2003.
DOI : 10.1189/jlb.0502244
URL : https://hal.archives-ouvertes.fr/hal-00192865

D. Riese, Specificity within the EGF family/ErbB receptor family signaling network, BioEssays, vol.16, issue.1, pp.41-49, 1998.
DOI : 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V

S. Oudard, M. Legrier, K. Boye, R. Bras-goncalves, D. Pinieux et al., Activity of Docetaxel With or Without Estramustine Phosphate Versus Mitoxantrone in Androgen Dependent and Independent Human Prostate Cancer Xenografts, The Journal of Urology, vol.169, issue.5, pp.1729-1763, 2003.
DOI : 10.1097/01.ju.0000062500.75703.2c

. Sebolt-leopold, Development of anticancer drugs targeting the MAP kinase pathway, Oncogene, vol.19, issue.56, pp.6594-6603, 2000.
DOI : 10.1038/sj.onc.1204083

J. Sebolt-leopold, D. Dudley, R. Herrera, K. Van-becelaere, A. Wiland et al., Saltiel AR Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo, Nature Medicine, vol.5, issue.7, pp.810-816, 1999.
DOI : 10.1038/10533

B. Gay, S. Suarez, G. Caravatti, P. Furet, and T. Meyer, Selective GRB2 SH2 inhibitors as anti-Ras therapy, International Journal of Cancer, vol.49, issue.8, pp.235-276, 1999.
DOI : 10.1002/(SICI)1097-0215(19991008)83:2<235::AID-IJC15>3.0.CO;2-B

B. Ramaswamy and S. Puhalla, Docetaxel: A tubulin-stablizing agent approved for the management of several solid, Drugs of Today, vol.42, issue.4, pp.265-79, 2006.
DOI : 10.1358/dot.2006.42.4.968648

M. Wolfson and C. Yang, Taxol induces tyrosine phosphorylation of SHC and its association with GRB2 in murine raw 264.7 cells, International Journal of Cancer, vol.70, issue.2, pp.248-52, 1997.
DOI : 10.1002/(SICI)1097-0215(19970117)70:2<248::AID-IJC17>3.0.CO;2-E

S. Lim, G. Lopez-berestein, M. Hung, R. Lupu, and T. , Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells, Oncogene, vol.19, issue.54, pp.6271-6277, 2000.
DOI : 10.1038/sj.onc.1204014

M. Mano, A. Awada, A. Minisini, V. Durbecq, D. Leo et al., Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras???Raf???MAPK and PI3K???Akt pathways activation, The Breast, vol.13, issue.4, pp.347-356, 2004.
DOI : 10.1016/j.breast.2003.11.009

S. Kang, Z. Shi, K. Worthy, L. Bindu, P. Dharmawardana et al., Examination of Phosphoryl-Mimicking Functionalities within a Macrocyclic Grb2 SH2 Domain-Binding Platform, Journal of Medicinal Chemistry, vol.48, issue.12, pp.3945-3953, 2005.
DOI : 10.1021/jm050059m

S. Kang, K. Worthy, L. Bindu, M. Zhang, D. Yang et al., Design and Synthesis of 4-(??-Hydroxymalonyl)phenylalanine as a New Phosphotyrosyl Mimetic and Its Use in Growth Factor Receptor Bound 2 Src-Homology 2 (Grb2 SH2) Domain-Binding Peptides, Journal of Medicinal Chemistry, vol.48, issue.16, pp.5369-72, 2005.
DOI : 10.1021/jm050154v

K. Lee, H. Yoon, J. Kim, M. Roh, S. Lee et al., A dipalmitoyl peptide that binds SH3 domain, disturbs intracellular signal transduction, and inhibits tumor growth in vivo, Biochemical and Biophysical Research Communications, vol.296, issue.2, pp.434-476, 2002.
DOI : 10.1016/S0006-291X(02)00869-0

H. Kim, M. Jeong, M. Kong, M. Han, K. Son et al., Inhibition of Shc/Grb2 protein-protein interaction suppresses growth of, pp.104-105

S. Feller and M. Lewitzky, Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors, Current Pharmaceutical Design, vol.12, issue.5, pp.529-577, 2006.
DOI : 10.2174/138161206775474369